Hyperglycemia Diagnoses

Overview of Hyperglycemia and Diabetes Mellitus

• Diabetes Mellitus (DM) is the primary pathology resulting from hyperglycemia, characterized by the abnormal function of insulin.
• The severity of insulin dysfunction varies depending on the specific type of diabetes diagnosed.
• DM is typically chronic in nature regarding its development and progression.
• While primarily associated with disturbances in carbohydrate metabolism, DM also leads to significant disturbances in lipid and protein metabolism.
• The secondary complications associated with DM are of primary concern as they place a massive burden on the healthcare system and significantly impact the life expectancy and quality of life for individuals with the condition.

Tissue Vulnerability and Insulin Independence

• Certain tissues are at exceptionally high risk for damage in states of hyperglycemia, particularly when the condition is poorly managed.
• Many of these tissues are "non-insulin dependent," meaning they do not require insulin to facilitate the entry of glucose into the cells (insulin does not act as a "gatekeeper").
• In the presence of hyperglycemia, glucose freely enters these cells, leading to intracellular pathology and tissue destruction.
• Tissues with very fine microvasculature are also susceptible to elevated destruction.

Specifically Impacted Tissues

• Retina: Damage is primarily related to the microvasculature. Clinical findings on eye exams correspond to the pathology caused by hyperglycemia impacting the retinal blood vessels.
• Lens: These tissues are non-insulin dependent. Glucose passes through and accumulates in the lens, leading to complications such as cloudiness (cataracts).
• Kidneys: The glomerular mechanism contains superfine vasculature. Hyperglycemia results in significant hemodynamic and structural insult to the kidneys.
• Peripheral Nerves: These are non-insulin dependent and possess delicate microvasculature. They are easily damaged in states of hyperglycemia, leading to diabetic neuropathy.
• Blood Vessels:
  • Microvascular disease: Affects small vessels in the kidneys, retina (visual loss), and nerves.
  • Macrovascular disease: Commonly seen in Type 2 Diabetes, characterized by accelerated atherosclerotic changes due to prolonged hyperglycemia.

Clinical Signs and Symptoms of Diabetes Mellitus

• Individuals may remain asymptomatic for long periods before acknowledging symptoms or receiving a diagnosis.
• Clinical suspicion is appropriate if lab indicators or lifestyle factors suggest pathology, even in the absence of classic symptoms.

The Three P's (Classic Symptoms)

1. Polyuria: Increased urination. This is usually the first of the three P's to appear.
   • Mechanism: Glucose is osmotically active; as excess glucose is excreted in the urine, it pulls water with it, increasing urinary output.
2. Polydipsia: Increased thirst. This develops as a physiological response to the dehydration caused by polyuria.
3. Polyphagia: Increased hunger.

Additional Manifestations

• Recurrent Infections: Commonly manifests as Candida overgrowth, leading to frequent vaginal yeast infections or itching.
• Neuropathy: Typically presents as a bilateral, distal polyneuropathy, often described as a "stocking and glove" distribution.
  • Symptoms include burning pain (especially in the feet), and loss of position and vibration sense.
  • Can lead to decreased deep tendon reflexes.
  • May affect cranial nerves, specifically III (Oculomotor) and VI (Abducens).
• Bilateral Carpal Tunnel Syndrome: If a patient presents with bilateral carpal tunnel, clinicians must consider Diabetes Mellitus or Hypothyroidism as underlying causes.
• Sexual Impotence: A common early complaint in males, though frequently underreported due to the uncomfortable nature of the topic.
• Wound Healing: Impairment in the body's ability to heal wounds effectively.
• Cardiovascular Issues: Hypertension and general cardiovascular disease are common.
• Weight Trends: Type 1 is characterized by abrupt onset and unintentional weight loss. Type 2 is insidious and typically associated with being overweight or obese.
• Fat Catabolism: Accelerated fat catabolism is a hallmark characteristic of Type 1 DM. (Type 2 may show very brief, early periods of catabolism, but it is not characteristic).

Type 1 Diabetes Mellitus (T1DM)

• Description: An autoimmune condition where the body produces antibodies against the beta cells in the pancreas, leading to a dramatic decrease or total lack of insulin.
• Alternative Name: Insulin-Dependent Diabetes Mellitus (IDDM).
• Diagnosis: Usually clear from history and labs. The GAD (Glutamic Acid Decarboxylase) autoantibody test is the current standard for identifying the pancreatic autoimmune process.
• Demographics: Typically diagnosed in individuals less than $25$ years of age, often much younger.
• Physical Habitual: Patients tend to be lean or experience unintentional weight loss.
• Management:
  • Immediate referral to a pediatric endocrinologist (or a GP if the specialist is unavailable).
  • Injectable insulin therapy.
  • Blood glucose monitoring, preferably using Continuous Glucose Monitoring (CGM).
  • Hemoglobin $A1c$ testing every $3$ months initially, though this may be spaced out once management is stable.
  • Dietary recommendations and support groups.
• Caution: Fasting blood glucose or 2-hour postprandial tests may not provide valuable diagnostic information once the condition is established; history and $A1c$ are more critical.

Type 2 Diabetes Mellitus (T2DM)

• Description: Characterized by insulin resistance in peripheral tissues rather than the complete destruction of insulin-producing cells.
• Alternative Name: Non-Insulin Dependent Diabetes Mellitus (NIDDM). Note: This name is being phased out as severe, late-stage T2DM patients may eventually require insulin.
• Prevalence: Accounts for $80\%$ of all Diabetes Mellitus cases.
• Risk Factors: High likelihood of being overweight or obese.
• Ketosis: Generally non-ketosis prone, except in very severe, long-term poorly managed cases.
• Complications: Macrovascular changes and atherosclerosis are primary concerns due to the long-term development of the disease and its cardiovascular associations.

Management of T2DM

• The "ABCs" of Monitoring:
  • A ($A1c$): Goal is less than $7\%$.
  • B (Blood Pressure): Target is less than $130/80\,mmHg$.
  • C (Cholesterol): Benchmarks focus on HDL and Triglycerides.
• Weight Loss: Strongly associated with better blood sugar management.
• Exercise:
  • Aerobic: "Zone 2" exercise for $30$ minutes, $5$ times per week.
  • Resistance training: Increasing evidence suggests benefits for glucose management.
  • The best exercise is the one the patient will consistently perform.
• Dietary Principles:
  • Emphasis on whole foods.
  • Lower Glycemic Index (GI) or Glycemic Load (GL) carbohydrates.
  • High-fiber carbohydrates.
  • Minimizing refined carbohydrates.
• Pharmacology: Metformin is the first-line pharmaceutical intervention and is highly effective at lowering $A1c$. Insulin is reserved for progressed or poorly managed cases.
• Monitoring Frequency: $A1c$ every $3$ months initially. If stable after $9-12$ months, may move to every $6$ months. If lifestyle changes are highly successful, it may return to an annual test.

Latent Autoimmune Diabetes in Adults (LADA / Type 1.5)

• Description: A form of autoimmune diabetes that develops more slowly than Type 1.
• Demographics: Commonly diagnosed between the ages of $30$ and $50$.
• Misdiagnosis: Frequently misdiagnosed as Type 2 due to the later age of onset and slower progression.
• Triggers: Onset can be seeded by an "insult," such as illness, physical stress, or emotional stress, which triggers the autoimmune event.
• Markers: Positive for markers of pancreatic autoimmunity, specifically GAD autoantibodies.
• Clinical Course: Individuals may initially respond to oral medications (like Metformin), but treatment effectiveness typically fails after a few years, eventually requiring insulin.
• Distinguishing Sign: Unintentional weight loss in an individual appearing to have Type 2 DM should raise suspicion for LADA.

Secondary Diabetes and Gestational Diabetes

Secondary Diabetes Mellitus

• Resulting from a primary underlying condition:
  • Pancreatitis: Inflammation of the pancreas.
  • Endocrinopathies: Conditions leading to hypersecretion of Cortisol or Growth Hormone, which elevate blood sugar.
  • Drugs: Certain medications can induce secondary hyperglycemia.

Gestational Diabetes

• Definition: Impaired glucose tolerance first identified during pregnancy in a woman without a prior history of diabetes.
• Screening: Typically performed between weeks $24$ to $28$ of pregnancy.
  • 1st Step: $50\,g$ glucose dose followed by a 1-hour plasma glucose test. A result $> 140\,mg/dL$ is a positive screen.
  • 2nd Step: A 3-hour oral glucose tolerance test (OGTT) is used to confirm the diagnosis.
• Prognosis: Blood sugar often returns to normal parity post-pregnancy, though the mother has an increased future risk of DM.
• Risks to Pregnancy/Mother: High birth weight and size (macrosomia), hypertension, and increased risk of preeclampsia.
• Risks to Baby: Post-birth hypoglycemia, respiratory distress syndrome, and jaundice.

Prediabetes and Impaired Glucose Regulation

• Prediabetes: An overarching term for states where blood glucose is elevated but does not yet meet the diagnostic threshold for DM.
• Categories:
  • Impaired Fasting Glucose (IFG): Fasting Blood Glucose between $100 - 125\,mg/dL$.
  • Impaired Glucose Tolerance (IGT): 2-hour postprandial results between $140 - 199\,mg/dL$.
• Lab Marker ($A1c$): Range of $5.7\%$ to $6.4\%$.
• Significance: High risk for progression to Diabetes Mellitus and associated cardiovascular pathologies.
• Clinical Goal: Early intervention to prevent progression. Identification of insulin resistance may even precede the official diagnosis of prediabetes using standard tests.